As with Ibrance, availability for previously-treated patients was via the CDF while additional evidence of efficacy is gathered. Kisqali and Verzenios moved to routine funding last year. Keytruda ...

Pfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set back its hopes of even loftier sales – and set up a challenge from Eli Lilly’s ...

Ibrance treatment doesn’t last a set number of years. You can take Ibrance for as long as you and your doctor feel it’s effective. Or you might take it until side effects are too severe ...

The profitability screen requires that the sum of a company’s GAAP earnings over the past four quarters be positive as well as the most recent quarter. The screen imparts a slight quality tilt ...

MoA International Fund earns a High Process Pillar rating. The largest contributor to the rating is its parent firm's superior long-term risk-adjusted performance, as shown by the firm's average ...

The rising global incidence of breast cancer, driven by lifestyle changes and an aging population, is a key market driver. Technological advancements in diagnostics and treatment, such as molecular ...